title: Long-term changes in glutamatergic synaptic transmission in phenylketonuria.
abstract: The cellular mechanisms that underlie impaired brain function during phenylketonuria (PKU), the most common biochemical cause of mental retardation in humans, remain unclear. Acute application of L-Phe at concentrations observed in the PKU brain depresses glutamatergic synaptic transmission but does not affect GABA receptor activity in cultured neurons. If these depressant effects of L-Phe take place in the PKU brain, then chronic impairment of the glutamate system, which may contribute to impaired brain function, could be detected as changes in postsynaptic glutamate receptors. This hypothesis was tested by using a combination of liquid chromatography-mass spectrometry, patch-clamp, radioligand binding and western blot approaches in forebrain tissue from heterozygous and homozygous (PKU) Pah(enu2) mice. Brain concentrations of L-Phe were nearly six-fold greater in PKU mice (863.12 +/- 17.96 micromol/kg) than in their heterozygous counterparts (149.32 +/- 10.23 micromol/kg). This concentration is significantly higher than the K(B) of 573 microM for L-Phe to compete for N-methyl-D-aspartate (NMDA) receptors. Receptor binding experiments with [3H]MK-801 showed significant up-regulation of NMDA receptor density in PKU mice. Consistent with the depressant effects of L-Phe, expression of NMDA receptor NR2A and (RS)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor Glu1 and Glu2/3 subunits was significantly increased, whereas expression of the NR2B subunit was decreased. There was no change in GABA alpha1 subunit expression. Given the role of the glutamatergic system in brain development and function, these changes may, at least in part, explain the brain disorders associated with PKU.
authors.affiliation: Department of Anesthesiology, University of Florida, Gainesville, FL 32610-0254, USA.
authors.forename: A V
authors.initials: AV
authors.lastname: Glushakov
authors.forename: O
authors.initials: O
authors.lastname: Glushakova
authors.forename: M
authors.initials: M
authors.lastname: Varshney
authors.forename: L K
authors.initials: LK
authors.lastname: Bajpai
authors.forename: C
authors.initials: C
authors.lastname: Sumners
authors.forename: P J
authors.initials: PJ
authors.lastname: Laipis
authors.forename: J E
authors.initials: JE
authors.lastname: Embury
authors.forename: S P
authors.initials: SP
authors.lastname: Baker
authors.forename: D H
authors.initials: DH
authors.lastname: Otero
authors.forename: D M
authors.initials: DM
authors.lastname: Dennis
authors.forename: C N
authors.initials: CN
authors.lastname: Seubert
authors.forename: A E
authors.initials: AE
authors.lastname: Martynyuk
mesh_terms: D000818:Animals; D015153:Blotting, Western; D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D006801:Humans; D013058:Mass Spectrometry; D051379:Mice; D018408:Patch-Clamp Techniques; D010649:Phenylalanine / Q000378:metabolism; D010661:Phenylketonurias / Q000378:metabolism / Q000503:physiopathology*; D017470:Receptors, Glutamate / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D009435:Synaptic Transmission
chemical_list: D017470:Receptors, Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D010649:Phenylalanine